Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris 03:06:10 2024-04-25 am EDT 5-day change 1st Jan Change
88.65 EUR +1.08% Intraday chart for Sanofi +3.97% -1.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sanofi: quarterly EPS down by more than 7% at TCC CF
Wall Street: a note of weakness ahead of US GDP figures CF
Sanofi Posts Lower Q1 Net Income; Net Sales Up MT
Sanofi Sales, Profit Beat Expectations DJ
Sanofi Q1 profit slips on generic competition, forex effects RE
EMEA Morning Briefing : Shares Seen Lower; Earnings, U.S. GDP Data in Focus DJ
SANOFI : Bernstein remains its Buy rating ZD
Sanofi to Enlist Banks for $20 Billion Consumer-health Spinoff MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care MT
Sanofi Asks Banks to Pitch for Roles on Separation of Consumer Health Care Business MT
Sanofi Is Said To Ask Banks To Pitch For $20 Billion OTC Spinoff - Bloomberg News RE
CAC40: up sharply, back over 8100 pts CF
CAC40: back to 8100, E-Stoxx to 5000, Nasdaq +1.5 CF
CAC40: closes in on 8,100, well supported by W-Street CF
CAC40: up slightly after encouraging PMI figures CF
Sanofi: positive phase III data in IPT CF
Sanofi Reports Positive Results from Phase 3 Trial of Rilzabrutinib for Immune Thrombocytopenia MT
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial DJ
Sanofi Reaches $100 Million Settlement for US Lawsuits Over Zantac Cancer Claims MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations MT
Top Midday Stories: Verizon Shares Down, Truist Shares Up Post Earnings; CNH Industrial Names New Chief Executive; Tesla Dissolves Newly Created Marketing Team MT
Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer MT
Sanofi Reportedly Agrees to Settle Zantac Cancer Lawsuits for More Than $100 Million MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
87.7 EUR
Average target price
107.8 EUR
Spread / Average Target
+22.87%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi, Regeneron Win EU Panel's Backing for Dupixent to Treat Atopic Dermatitis in Children